Table 2 Study cohort clinical features
From: Clinical implications of prospective genomic profiling of metastatic breast cancer patients
|  | Overall (n = 322) | ER+HER2− (n = 219, 68%) | HER2+ (n = 38, 12%) | TNBC (n = 65, 20%) | P value |
|---|---|---|---|---|---|
Median age at primary diagnosis (range) | 46 (23–74) | 46 (24–73) | 43.5 (34–74) | 47 (23–74) |  |
Median age at metastatic diagnosis (range) | 51 (24–78) | 52 (30–78) | 45.5 (35–67) | 50 (24–76) |  |
Median age at consent (range) | 52 (24–81) | 54 (30–78) | 48 (36–81) | 52 (24–77) |  |
Median DFI1 (range) | 40 (1–312) | 54.5 (1–312) | 25 (4–136) | 23 (1–252) |  |
De novo patients | 71 (22%) | 50 (22%) | 14 (36%) | 7 (11%) | Â |
Treatment history | |||||
 Previous chemotherapy | |||||
  Yes | 309 (96%) | 208 (95%) | 37 (97%) | 64 (98%) |  |
  No | 8 (2%) | 7 (3%) | 1 (3%) | 0 |  |
  Unknown | 5 (2%) | 4 (2%) | 0 | 1 (2%) |  |
 Previous Endocrine therapy |  |  |  |  | Chi squared: < 0.0001 |
  Yes | 222 (69%) | 205 (94%) | 11 (29%) | 6 (9%) |  |
  No | 95 (29%) | 10 (5%) | 27 (71%) | 58 (89%) |  |
  Unknown | 5 (2%) | 4 (1%) | 0 | 1 (2%) |  |
 Lines of treatment in metastatic setting |  |  |  |  | Chi squared: 0.003 |
  1 | 28 (9%) | 12 (5%) | 1 (3%) | 16 (25%) |  |
  2 | 70 (22%) | 47 (21%) | 4 (11%) | 19 (29%) |  |
  3 | 72 (22%) | 45 (21%) | 13 (34%) | 14 (22%) |  |
  > 3 | 133 (41%) | 103 (47%) | 20 (53%) | 10 (15%) |  |
  Unknown | 20 (6%) | 12 (5%) | 0 | 6 (9%) |  |
 Sequenced patients | |||||
  Sequenced | 234 (72%) | 162 (75%) | 25 (66%) | 47 (72%) |  |
  Not sequenced due to sample failure | 18 (6%) | 12 (6%) | 1 (3%) | 5 (8%) |  |
  Not sequenced due to other2 | 70 (22%) | 45 (19%) | 12 (31%) | 13 (20%) |  |
 Patients with actionable mutations3 | 171 (74%) | 131 (80%) | 11 (44%) | 29 (61%) | Chi squared: 0.0001 |
  Level 1: | 114 (49%) | 93 (57%) | 6 (24%) | 15 (32%) |  |
  Level 2 | 57 (25%) | 38 (24%) | 5 (20%) | 14 (30%) |  |
  No actionable alterations | 63 (26%) | 31 (19%) | 14 (56%) | 18 (38%) |  |